SafeSciMET ( presents a new and unique pan-European education and training network.

In current drug safety education and training in Europe, an integrative and translational approach is lacking. SafeSciMET aims to solve this shortfall by developing and establishing a comprehensive modular Education & Training Programme in Safety Sciences for Medicines (SafesciMET).

This programme will fulfil the needs of Pharmaceutical Industry, Regulatory Authorities and Academia. The network, consisting of top institutes for drug safety education and research, proposes a new type, high quality and sustainable programme for education and training in Safety Sciences for Medicines (S2M).

The tailor-made training courses will encompass the safety, ethical, regulatory and societal aspects in all phases of drug development, with emphasis on integrative, translational and 3Rs aspects of drug safety assessment.

Individual safety professionals who wish to address specific knowledge gaps will be able to follow single courses. The modular set up also provides an excellent opportunity for following dedicated subsets of courses, to be accredited for Continuing Professional Development (CPD).

Scientists successfully completing the full programme, including an integrative MSc-thesis, will be awarded with an accredited Master of Advanced Safety Sciences of Medicines (MAS2M). pAll training courses and procedures will be aligned with the Bologna process.pSafeSciMET is funded by the Innovative Medicines Initiative Joint Undertaking (IMI JU).

  • FB Biologie
Name Finanzierungstyp Kategorie Kennziffer
Europäische Union Drittmittel Forschungsförderprogramm 428/10
Weitere Informationen
Laufzeit: 01.01.2010 – 31.12.2014